NKF(SH:603707)2022-04-26 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥1,176,560,687.58, representing a year-on-year increase of 33.24%[4] - The net profit attributable to shareholders for the same period was ¥330,089,249.36, reflecting a growth of 20.96% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥326,094,976.70, which is an increase of 23.68% year-on-year[4] - The basic and diluted earnings per share were both ¥0.27, up by 22.73% year-on-year[5] - The total operating revenue for Q1 2022 reached CNY 1,176,560,687.58, a significant increase of 33.3% compared to CNY 883,052,586.38 in Q1 2021[21] - The total operating costs for Q1 2022 were CNY 788 million, up from CNY 568 million in Q1 2021, indicating a rise of 38.7%[22] - The net profit for Q1 2022 was CNY 330.53 million, compared to CNY 273.22 million in Q1 2021, reflecting an increase of 21.0%[23] - The total comprehensive income for Q1 2022 was CNY 329.93 million, compared to CNY 274.71 million in Q1 2021, showing an increase of 20.1%[23] Cash Flow and Assets - The net cash flow from operating activities reached ¥252,013,310.86, showing a significant increase of 3,999.30% compared to the same period last year[4] - Current assets totaled CNY 7,337,484,043.53 as of March 31, 2022, up from CNY 6,929,829,957.54 at the end of 2021, reflecting a growth of approximately 5.9%[19] - Cash and cash equivalents increased to CNY 1,022,950,850.98 from CNY 658,552,787.15, marking a growth of 55.3% year-over-year[18] - The total cash inflow from operating activities in Q1 2022 was CNY 1.12 billion, compared to CNY 960.82 million in Q1 2021, reflecting an increase of 16.5%[25] - The total cash and cash equivalents at the end of the period amounted to 667,705,647.21 CNY, a decrease from 1,834,550,193.98 CNY at the end of the previous year[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥8,772,844,820.78, an increase of 6.77% from the end of the previous year[5] - Total liabilities increased to CNY 3,047,055,052.83 from CNY 2,814,131,012.41, representing a rise of 8.3%[20] - The company's total assets reached CNY 8,772,844,820.78, an increase from CNY 8,216,888,051.71, reflecting a growth of 6.8%[20] - Non-current assets amounted to CNY 1,435,360,777.25, up from CNY 1,287,058,094.17, indicating an increase of 11.5%[19] Shareholder Information - The company had a total of 12,164 ordinary shareholders at the end of the reporting period, with the largest shareholder holding 27.20% of the shares[9] - The equity attributable to shareholders increased to ¥5,700,893,695.09, marking a growth of 6.01% compared to the previous year[5] - The total equity attributable to shareholders increased to CNY 5,700,893,695.09 from CNY 5,377,921,396.15, reflecting a growth of 6.0%[20] Product Development and Market Strategy - The increase in operating revenue was driven by the rapid growth in sales following the approval and launch of injection products[8] - The company received the drug registration certificate for injectable calcium levofolinate from the National Medical Products Administration and the FDA approval for furosemide injection, enhancing its product pipeline in the oncology sector[12] - Key products such as heparin sodium injection and nadroparin calcium injection have been shortlisted for centralized procurement in Guangdong Province and Inner Mongolia, indicating successful exploration of the centralized procurement sales model[13] - Overseas formulation sales increased by over 30% compared to the same period last year, with significant growth in Europe and other global markets, establishing overseas sterile injection sales as a key growth driver[14] - The company is implementing lean management practices to improve operational efficiency and product quality, focusing on systematic improvements across production, quality, research, registration, marketing, and sales[15] - The company has established a complete sales channel in the U.S. market and acquired the Meitheal team to enhance its marketing strategy and localize its operations in the U.S.[16] - The company is leveraging internet platforms to support sales partners and expand the number of formulations entering hospitals, aiming to increase sales volume in a competitive market[13] - The company is committed to a "zero defect" quality standard, ensuring that its products meet the highest global regulatory requirements, which is fundamental to its long-term competitiveness[16] - The company is enhancing its procurement strategy by deepening relationships with key suppliers and optimizing supply chain management to ensure stable raw material supply[16] - The company is utilizing third-party clinical representatives to promote products and gather real-time market feedback, effectively expanding its sales channels and hospital coverage[17] - The company plans to launch more consistency evaluation products in the coming years, strengthening its marketing team to adapt to market needs and policies[13] Research and Development - Research and development expenses for Q1 2022 amounted to CNY 53.46 million, an increase from CNY 33.91 million in Q1 2021, representing a growth of 57.6%[22] Tax and Expenses - The tax expenses for Q1 2022 were CNY 59.24 million, up from CNY 40.29 million in Q1 2021, indicating a rise of 47.1%[23]